International

AstraZeneca hits snag in Covid drug development

AFP/Editor

Pharmaceutical giant AstraZeneca on Tuesday revealed it had hit a setback in trials of a treatment for Covid-19 symptoms.

The drug, made from a combination of two antibodies, failed its main goal to treat symptoms in exposed patients, the company said in a statement.

The treatment has been undergoing phase 3 or final-stage clinical trials to assess its safety and efficacy.

AstraZeneca said that 1,121 unvaccinated adults had been exposed to an infected person as part of the trial.

20260101_dengue_cubeta_728x90

Treatment AZD7442 reduced the risk of developing symptoms by only 33 percent — which was “not statistically significant”, it added.

The company is nevertheless continuing trials to assess whether the drug can prevent Covid or treat more severe symptoms.

The US government has funded the development of AZD7442 and has agreements to receive 700,000 doses.

Meanwhile, AstraZeneca’s Covid vaccine, which was developed with the University of Oxford, faced fresh safety doubts.

The jab has been suspended in several European countries over reports of rare blood clots.

20260101_dengue_cubeta_728x90

A top official in the European Medicines Agency was on Sunday reported as having suggested that it might be worth abandoning AstraZeneca’s vaccine if alternatives were available.

But the EMA said the body’s head of vaccine strategy, Marco Cavaleri, had been misrepresented, and that he believed its benefits outweigh its risks.

“The decision on its use in different populations and ages is the prerogative of the EU Member States, based on specific factors such as virus circulation and vaccine availability,” a spokeswoman said.

A study from British health authorities published on Monday found that two doses of AstraZeneca/Oxford or rival Pfizer/BioNTech vaccines stopped the need for in-patient treatment in more than 90 percent of cases of the Delta variant.

The UK government on Monday announced a four-week delay to the full lifting of coronavirus restrictions in England due to a surge in infections caused by Delta, which first appeared in India.

20260101_dengue_cubeta_728x90

International

Luigi Mangione Pleads Guilty to Killing UnitedHealthcare CEO Brian Thompson

Luigi Mangione admitted Friday to fatally shooting Brian Thompson, the CEO of UnitedHealthcare, the largest health insurance group in the United States, during an appearance before a federal judge.

The case shocked the U.S. business community and dates back to December 2024, when Mangione opened fire on Thompson, 50, on a Manhattan street. Prosecutors have described the attack as being motivated by Mangione’s opposition to the U.S. health insurance system.

“On the morning of December 4, I shot Mr. Thompson in Manhattan and he died,” Mangione said as he pleaded guilty to a federal stalking charge related to his pursuit of the executive.

Mangione, 28, is scheduled to be sentenced on December 18, and prosecutors have indicated that they will seek a life sentence.

In addition to the federal charges related to stalking Thompson, Mangione also faces a murder case brought by the state of New York.

Following his guilty plea in federal court, Mangione’s defense asked a state court to dismiss the state charges, arguing that prosecuting him again for the same conduct would violate protections against double jeopardy.

“We have just filed our motion in state court to explain why the charges should be dismissed under New York’s protections against double jeopardy,” Mangione’s attorney, Karen Friedman Agnifilo, said Friday.

Both the federal and state cases could result in a life sentence. Two other federal charges that initially carried the possibility of the death penalty were dismissed by a judge earlier this year.

International

ICE Plan to Equip Agents With Electric Shock Gloves Raises Abuse Concerns

Plans to equip U.S. immigration agents with gloves capable of delivering electric shocks are raising concerns over potential abuses by a law enforcement agency that critics accuse of using excessive force and providing inadequate training to its personnel.

The plan involves the potential purchase of electric-shock gloves for agents with U.S. Immigration and Customs Enforcement (ICE), the agency primarily responsible for carrying out President Donald Trump’s campaign to deport millions of undocumented immigrants.

Democratic Representative Maxwell Frost criticized the proposal on X, arguing that the agency has already faced accusations of excessive force during immigration enforcement operations.

“As if assaulting and shooting people in the streets wasn’t enough,” Frost wrote. He also criticized the reported $20 million potential expenditure on the devices and called for greater restrictions on ICE.

The agency has faced growing scrutiny following a series of deadly shootings during immigration enforcement operations. Among the incidents were the deaths of two U.S. citizens in Minnesota in January who were participating in protests against the agency.

Critics have focused on the tactics used by ICE agents when detaining immigrants, as well as allegations that training standards for newly recruited personnel have been lowered.

According to a procurement plan first reported by the Associated Press, the Department of Homeland Security (DHS), which oversees ICE, could spend between $10 million and $20 million on the devices.

The gloves are described by the agency as tools intended for “distraction and de-escalation,” rather than lethal weapons. The system, known as GLOVE, stands for “Generated Low-Output Voltage Emitter.”

The device is manufactured by Compliant Technologies, a Kentucky-based company that describes its products as advanced non-lethal tools designed to protect and assist law enforcement and other personnel.

The proposal comes amid an intensifying national debate over ICE’s enforcement methods and the use of force during the Trump administration’s immigration crackdown.

International

Three U.S. Executions Set for Same Day as Trump Pushes to Expand Death Penalty

The death penalty has been abolished in 23 of the 50 U.S. states, while three others —California, Oregon and Pennsylvania— currently have moratoriums in place.

The United States is set to carry out three executions on the same day, a rare occurrence that has not happened since 2010, according to the nonprofit Death Penalty Information Center.

President Donald Trump has sought to expand the use of capital punishment for what he describes as “the most heinous crimes.” In April, the Department of Justice proposed expanding execution methods to include firing squads, lethal gas and electrocution.

Tennessee is scheduled to execute Anthony Darrell Dugard Hines, 66, on Thursday. He was sentenced to death for the 1985 murder of a woman, according to local media.

In Oklahoma, Carlos Cuesta-Rodríguez, 70, is scheduled to be executed for a 2003 murder.

20260101_dengue_cubeta_728x90

Meanwhile, Alabama plans to execute Jeremy Williams, 42, who was sentenced to death for the rape and murder of a five-year-old girl.

The United States carried out 47 executions in 2025, the highest number since 2009, when 52 executions were recorded.

Florida conducted the largest number of executions last year, with 19, followed by Alabama, South Carolina and Texas, with five each.

Of the executions carried out in 2025, 39 were conducted by lethal injection. Three were carried out by firing squad and five through nitrogen hypoxia, a method that involves forcing nitrogen gas into a face mask, depriving the prisoner of oxygen.

The United Nations has condemned nitrogen gas as a cruel and inhumane method of capital punishment.